Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial (Forbes)

Novo Nordisk announced promising early-stage trial results for its new weight loss pill, amycretin, which showed up to 13% body weight loss in 12 weeks, surpassing the results of its blockbuster injection Wegovy. The study suggests similar side effects to other GLP-1-based drugs like Ozempic. With rising competition from pharma giants like Eli Lilly, Novo is considering accelerating amycretin’s development. If successful, the drug could represent a major shift in obesity treatment. Stock prices for Novo Nordisk surged following the news.